Is Ozempic Safe Long Term? What the Evidence Actually Shows

As semaglutide use becomes more widespread, one of the most common questions from prospective and current users is: is it actually safe to stay on this medication for years? Here is what the evidence currently shows.

What Long-Term Safety Data Exists?

The SELECT trial (2023) followed over 17,000 participants taking semaglutide 2.4mg for up to 5 years and found significant reductions in cardiovascular events with an acceptable safety profile. The SUSTAIN and STEP trial programmes also include multi-year follow-up data showing sustained tolerability. These are among the most robust long-term datasets available for any weight management medication.

Thyroid Risk: What You Need to Know

Semaglutide carries an FDA black box warning for thyroid C-cell tumours based on animal studies — specifically rodent studies that showed elevated rates of medullary thyroid carcinoma (MTC) at doses far exceeding human equivalents. Importantly, this effect has not been observed in human studies to date. The warning is precautionary. People with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2) should not use semaglutide.

Pancreatitis Risk

There is a small elevated risk of acute pancreatitis associated with GLP-1 receptor agonists as a class. The absolute risk is low, but people with a history of pancreatitis or significant alcohol use should discuss this carefully with their physician. Symptoms to watch for: severe persistent abdominal pain, especially radiating to the back.

Muscle Loss

This is arguably the most underappreciated long-term risk. Rapid weight loss on semaglutide — especially without adequate protein intake and resistance training — can result in significant lean muscle mass loss alongside fat loss. Over years, this can worsen metabolic rate, physical function, and body composition. The mitigation strategy is clear: maintain high protein intake (100–150g/day) and strength train regularly throughout treatment.

Gallbladder Issues

Rapid weight loss increases gallstone risk, and semaglutide-induced weight loss is no exception. Studies have shown a slightly elevated rate of gallbladder disease in semaglutide users compared to placebo. This is worth monitoring, particularly in people with existing gallbladder history.

The Case for Long-Term Use

Obesity is a chronic, relapsing disease with its own long-term health risks that dramatically outweigh the risks of semaglutide for most people. The SELECT trial demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events by 20% over ~3.3 years in people with cardiovascular disease and obesity. Major professional bodies including the American Diabetes Association and Obesity Medicine Association now recommend treating obesity as a chronic condition — which implies long-term, possibly lifelong medication use.

What Happens If You Stop?

The evidence is consistent: most weight returns within 1–2 years of stopping semaglutide. This is not a failure of willpower — it reflects that the medication is treating the biological drivers of obesity. Stopping it removes that treatment. For many people this supports the case for indefinite use under physician supervision, similar to taking blood pressure or cholesterol medication long-term.

Monitoring Recommendations

For people on long-term semaglutide, physician-supervised programmes typically include: regular blood glucose monitoring, periodic thyroid checks, lipid panels, kidney function tests, and body composition tracking to detect muscle loss early. This is one reason physician-supervised programmes are strongly preferred over unsupervised use.

Affiliate disclosure: This article contains affiliate links. See our Affiliate Disclosure.